Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences.

VCN is Developing a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors.

For additional details, click here.

Next time someone asks what you're made of,tell them trillions of microbial cells.

Your gut microbiome contains a large community of microbes, including bacteria, archaea, protists, fungi and viruses. Most live in your digestive tract, affecting everything from your immune system to your metabolism.

Let's get to know each other.

FIND US AT AN EVENT NEAR YOU

Wide scientific roots

We are pioneering microbiome science rooted in the gastrointestinal (GI) tract to advance innovative therapeutics designed to protect and preserve your health. Our team is comprised of industry leaders and veterans with wide-ranging scientific and manufacturing roots who are keenly focused on developing and advancing ground breaking microbiome research in support of our novel pipeline of GI-focused therapeutics.

Learn more about our science

A deep, GI-focused pipeline rooted in microbiome research

Our two lead candidates include:

Candidate & Indication	Development Stage
	Preclinical	Phase 1	Phase 2	Phase 3	Market
	SYN-004 (ribaxamase) Prevention of C. diff, pathogenic overgrowth and the emergence of antimicrobial resistance
SYN-004 (ribaxamase) Prevention of C. diff, pathogenic overgrowth and the emergence of antimicrobial resistance	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase complete	Phase 3 Phase not started	Market Phase not started
	SYN-020 Celiac disease, NAFLD, radiation enteritis, and age-related metabolic and inflammatory diseases
SYN-020 Celiac disease, NAFLD, radiation enteritis, and age-related metabolic and inflammatory diseases	Preclinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started	Market Phase not started
	SYN-004 (ribaxamase) Prevention of aGVHD, CDI & VRE colonization in allogeneic HCT recipients
SYN-004 (ribaxamase) Prevention of aGVHD, CDI & VRE colonization in allogeneic HCT recipients	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	Market Phase not started

See our comprehensive pipeline

A simple, solid philosophy

Develop simple therapeutics that have the potential to influence the microbiome to treat and prevent diseases of the gastrointestinal tract in order to protect the health of patients, who are at the heart of what we do.

Our company and science

Our innovative GI-focused development pipeline is designed to address large unmet medical needs and safeguard patient wellness.

Fill out the form below for more information.

*Required